Relmada Therapeutics Inc. (RLMD) 2.5000 $RLMD
Relmada Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 09, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 2:00 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
Relmada Therapeutics Selects MepiGel Formulations to Advance Into Clinical Studies
PR Newswire - Wed Feb 04, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has selected the formulations to be advanced into clinical studies for MepiGel, the company's topical dosage form of the local anesthetic mepivacaine being studied for the treatment of neuropathic pain.
Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference
PR Newswire - Fri Jan 16, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will provide a business overview and update at the Noble Financial Capital Markets Equity Conference being held on January 18-21, 2015 in Sandpiper Bay, Florida.
Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone
PR Newswire - Tue Jan 13, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has reached the midway point in a continuing pharmacokinetic and pharmacodynamic study with d-Methadone, the company's N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain. The midway point in the dosing study has been reached with no evidence of dose-limiting toxicity.
Relmada Therapeutics to Present at OneMedForum in San Francisco
PR Newswire - Wed Jan 07, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company will present a business overview and update at the OneMedForum investor conference at 8:50 AM Pacific Time (11:50 AM Eastern Time) on Tuesday, January 13, 2015. The presentation will take place at the Marriott Marquis Hotel in San Francisco.
Relmada Therapeutics to Provide Corporate Update at 2015 Biotech Showcase(TM) in San Francisco
PR Newswire - Tue Jan 06, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 7th Annual Biotech Showcase(TM) Conference at 11:00 AM Pacific Time (2:00 PM Eastern Time) on Tuesday, January 13, 2015. The presentation will take place in the D - Powell (3rd Floor) track at the Parc 55 Wyndham Hotel in San Francisco.
Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone
PR Newswire - Mon Dec 22, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the first cohort of subjects has been dosed in a pharmacokinetic and pharmacodynamic study with d-Methadone, the company's N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain.
Diabetic Neuropathic Pain - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/qm4xdv/diabetic) has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - Eli Lilly and Company - BioDelivery Sciences - Daiichi Sankyo - Acorda Therapeutics - Astellas Pharma - Glenmark Pharmaceuticals - KunWha Pharmaceutical - Mertiva - Grunenthal - Kyorin Pharmaceutical - Bial - Lohocla Research - Relmada Therapeutics - Sphaera Pharma - Immune Pharmaceuticals - AbbVie - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/qm4xdv/diabetic
IMNP: 1.87 (-0.03), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), ACOR: 36.14 (-0.51)
Relmada Therapeutics Announces Results of Annual Shareholders Meeting
PR Newswire - Thu Dec 18, 3:35PM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced the results of its annual general meeting of shareholders held today.
Postherpetic Neuralgia - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/489mg3/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Allergan - Acorda Therapeutics - Daewoong Pharmaceutical - Pfizer - Purdue Pharma - Teva Pharmaceutical Industries - Nuvo Research Inc. - Arcion Therapeutics, Inc. - NeurAxon, Inc. - Winston Pharmaceuticals, Inc. - Bial - Portela & Ca, S.A. - Spinifex Pharmaceuticals Pty Limited - Relmada Therapeutics, Inc. - Aestus Therapeutics, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Immune Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/48...stherpetic
AGN: 229.49 (+1.87), TEVA: 56.77 (-0.58), IMNP: 1.87 (-0.03), BMY: 60.04 (+0.56), ACOR: 36.14 (-0.51)
Relmada Therapeutics hires Christine Silverstein as director of Investor Relations
M2 - Thu Dec 11, 6:17AM CST
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) revealed on Wednesday the election of Christine Silverstein as director of its investor relations.
Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations
PR Newswire - Wed Dec 10, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Christine Silverstein as director of investor relations, effective immediately. She will report to Michael Becker, senior vice president of finance and corporate development at Relmada.
Relmada Therapeutics to begin first pharmacokinetic and pharmacodynamic study of d-Methadone for neuropathic pain in Canada
M2 - Wed Dec 03, 7:09AM CST
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) reported on Tuesday the receipt of Health Canada's No Objection Letter (NOL) to start the first pharmacokinetic and pharmacodynamic study of its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain, d-Methadone.
Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference
PR Newswire - Wed Dec 03, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, is pleased to participate in the Buzz of BIO Contest in connection with the 2015 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference features leading private and emerging public companies and will take place February 9-10, 2015 at the Waldorf Astoria in New York, NY.
Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
PR Newswire - Tue Dec 02, 7:30AM CST
Novel Product Virtually Devoid of Opioid Activity Being Studied in Neuropathic Pain.
Relmada Therapeutics To Present At LD MICRO Conference
PR Newswire - Mon Nov 24, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, is scheduled to present at the LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California.
Relmada Therapeutics hires Michael Becker as SVP of finance and corporate development to broaden and strengthen its senior leadership team
M2 - Wed Nov 05, 6:31AM CST
Biopharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday the election of Michael D. Becker as senior vice president of its finance and corporate development with immediate effect.
Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
PR Newswire - Tue Nov 04, 7:00AM CST
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.
Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
Marketwired - Wed Oct 29, 8:08AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.
Relmada Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 09, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the Company will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 2:00 p.m. Eastern Time. The conference will take place at the Waldorf Astoria Hotel in New York City.
Relmada Therapeutics Selects MepiGel Formulations to Advance Into Clinical Studies
PR Newswire - Wed Feb 04, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has selected the formulations to be advanced into clinical studies for MepiGel, the company's topical dosage form of the local anesthetic mepivacaine being studied for the treatment of neuropathic pain.
Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference
PR Newswire - Fri Jan 16, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will provide a business overview and update at the Noble Financial Capital Markets Equity Conference being held on January 18-21, 2015 in Sandpiper Bay, Florida.
Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone
PR Newswire - Tue Jan 13, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has reached the midway point in a continuing pharmacokinetic and pharmacodynamic study with d-Methadone, the company's N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain. The midway point in the dosing study has been reached with no evidence of dose-limiting toxicity.
Relmada Therapeutics to Present at OneMedForum in San Francisco
PR Newswire - Wed Jan 07, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company will present a business overview and update at the OneMedForum investor conference at 8:50 AM Pacific Time (11:50 AM Eastern Time) on Tuesday, January 13, 2015. The presentation will take place at the Marriott Marquis Hotel in San Francisco.
Relmada Therapeutics to Provide Corporate Update at 2015 Biotech Showcase(TM) in San Francisco
PR Newswire - Tue Jan 06, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 7th Annual Biotech Showcase(TM) Conference at 11:00 AM Pacific Time (2:00 PM Eastern Time) on Tuesday, January 13, 2015. The presentation will take place in the D - Powell (3rd Floor) track at the Parc 55 Wyndham Hotel in San Francisco.
Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone
PR Newswire - Mon Dec 22, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the first cohort of subjects has been dosed in a pharmacokinetic and pharmacodynamic study with d-Methadone, the company's N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain.
Diabetic Neuropathic Pain - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/qm4xdv/diabetic) has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - Eli Lilly and Company - BioDelivery Sciences - Daiichi Sankyo - Acorda Therapeutics - Astellas Pharma - Glenmark Pharmaceuticals - KunWha Pharmaceutical - Mertiva - Grunenthal - Kyorin Pharmaceutical - Bial - Lohocla Research - Relmada Therapeutics - Sphaera Pharma - Immune Pharmaceuticals - AbbVie - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/qm4xdv/diabetic
IMNP: 1.87 (-0.03), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), ACOR: 36.14 (-0.51)
Relmada Therapeutics Announces Results of Annual Shareholders Meeting
PR Newswire - Thu Dec 18, 3:35PM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced the results of its annual general meeting of shareholders held today.
Postherpetic Neuralgia - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/489mg3/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Allergan - Acorda Therapeutics - Daewoong Pharmaceutical - Pfizer - Purdue Pharma - Teva Pharmaceutical Industries - Nuvo Research Inc. - Arcion Therapeutics, Inc. - NeurAxon, Inc. - Winston Pharmaceuticals, Inc. - Bial - Portela & Ca, S.A. - Spinifex Pharmaceuticals Pty Limited - Relmada Therapeutics, Inc. - Aestus Therapeutics, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Immune Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/48...stherpetic
AGN: 229.49 (+1.87), TEVA: 56.77 (-0.58), IMNP: 1.87 (-0.03), BMY: 60.04 (+0.56), ACOR: 36.14 (-0.51)
Relmada Therapeutics hires Christine Silverstein as director of Investor Relations
M2 - Thu Dec 11, 6:17AM CST
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) revealed on Wednesday the election of Christine Silverstein as director of its investor relations.
Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations
PR Newswire - Wed Dec 10, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Christine Silverstein as director of investor relations, effective immediately. She will report to Michael Becker, senior vice president of finance and corporate development at Relmada.
Relmada Therapeutics to begin first pharmacokinetic and pharmacodynamic study of d-Methadone for neuropathic pain in Canada
M2 - Wed Dec 03, 7:09AM CST
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) reported on Tuesday the receipt of Health Canada's No Objection Letter (NOL) to start the first pharmacokinetic and pharmacodynamic study of its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain, d-Methadone.
Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference
PR Newswire - Wed Dec 03, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, is pleased to participate in the Buzz of BIO Contest in connection with the 2015 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference features leading private and emerging public companies and will take place February 9-10, 2015 at the Waldorf Astoria in New York, NY.
Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
PR Newswire - Tue Dec 02, 7:30AM CST
Novel Product Virtually Devoid of Opioid Activity Being Studied in Neuropathic Pain.
Relmada Therapeutics To Present At LD MICRO Conference
PR Newswire - Mon Nov 24, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, is scheduled to present at the LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California.
Relmada Therapeutics hires Michael Becker as SVP of finance and corporate development to broaden and strengthen its senior leadership team
M2 - Wed Nov 05, 6:31AM CST
Biopharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday the election of Michael D. Becker as senior vice president of its finance and corporate development with immediate effect.
Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
PR Newswire - Tue Nov 04, 7:00AM CST
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.
Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
Marketwired - Wed Oct 29, 8:08AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.
